Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Much “Ado” About Biosimilars

This article was originally published in RPM Report

Executive Summary

The approval of Kadcyla gives Roche/Genentech yet another new breakthrough cancer therapy in the US. It also offers some clues about the future of biosimilars at FDA.

Advertisement

Related Content

Biosimilar Naming Decision Nears as Applications Arrive At FDA
Which Came First? Alogliptin Avoids Possible Exclusivity Dispute
Genentech’s Cancer Product Line Expands, As Do Its Post-Market Manufacturing Obligations
Where Are The Biosimilars?
What's "New" at FDA?
FDA's Balancing Act: Early Hints at a Biosimilars

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS081111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel